Clinical Trial

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will assess whether adding one of the newest multiple myeloma therapies, daratumumab, into the Total Therapy approach helps patients live longer with fewer side effects
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2016-12-22; most recent amendment 2025-09-03.
Status change: Recruiting → Active, Not Recruiting 2020-10-09
Status change: Not Yet Recruiting → Recruiting 2017-07-07
Trial Details
NCT Number NCT03004287
Lead Sponsor University of Arkansas
Collaborators: Janssen, LP
Conditions Multiple Myeloma
Enrollment 50 participants
Start Date 2017-07-01
Primary Completion 2026-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2025-09-10